Press Releases
You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.
Asarina Pharma AB (publ) Interim Report Q2 2020 released
2020-08-19 08:00
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS MENSTRUAL MIGRAINE 95% of patients have been recruited in our Phase IIa proof-of-concept study. In total since...
Asarina Pharma AB (publ) Interim Report Q1 2020 released
2020-05-26 08:00
FINANCIAL HIGHLIGHTS SIGNIFICANT EVENTS DURING THE FIRST QUARTER PMDD In April 2020 we released inconclusive topline results from our phase IIb study in...
Dividend In accordance with the board's proposal, the AGM resolved that no dividend is to be paid for the financial year 2019. Discharge from liability...
Asarina Pharma reports topline results from Phase IIb study in PMDD
2020-04-21 19:30
“Obviously, we had hoped for a different outcome" says Peter Nordkild, CEO of Asarina Pharma. “To all women living with PMDD I can only...
Asarina Pharma Annual Report for 2019 released
2020-04-14 08:00
For further information see the attached, plus please visit https://asarinapharma.com/investors/financial-reports/ For further information, please contact...
NOTICE OF ANNUAL GENERAL MEETING IN asarina pharma AB (publ)
2020-04-02 08:30
The Company is closely monitoring the development of covid-19, the corona virus, and will revert with more information closer to the AGM if it is deemed...
Asarina Pharma to release historic Phase IIb PMDD data on schedule
2020-03-24 08:30
Asarina Pharma’s Phase IIb study into PMDD (premenstrual dysphoric disorder) was conducted in the UK, Germany, Poland and Sweden. Enrolment was completed...
Asarina Pharma R&D Day 2020 to go digital
2020-03-16 13:00
The event is scheduled for 14.00-16.00 on March 26 at: https://financialhearings.com/event/12815 Please register at: https://financialhearings.com/event/12602/register/live_event...
Invitation to Asarina Pharma R&D Day 2020
2020-03-05 13:00
Date: March 26, 2020 Time: 14.00-17.00, registration from 13.30 Location: Helio GT30, Grev Turegatan 30, Stockholm With presentations from PMDD practitioners...
Asarina Pharma AB (publ) Year-end 2019 Report released
2020-02-21 08:00
FINANCIAL HIGHLIGHTS PREMENSTRUAL DYSPHORIC DISORDER We enrolled the last patient in our Phase IIb study in our lead indication, Premenstrual Dysphoric...